About this Research Topic
The field of advanced biotechnology and nanotechnology is rapidly evolving, offering innovative solutions for the theragnostic of infectious lung diseases. Infectious pneumonia, a severe condition influenced by various factors such as pathogen type, patient health status, age, and immune system condition, remains a significant global health challenge. Pathogens including bacteria, viruses, fungi, and mycoplasma can lead to life-threatening pneumonia, necessitating precise and effective treatment strategies. The rise of multidrug-resistant bacteria and viruses has complicated treatment efforts, as traditional antibiotics often lack specificity and can disrupt beneficial bacterial communities. Recent studies have highlighted the potential of novel immunomodulators in regulating excessive inflammatory responses in severe lung infections, while vaccination continues to be a critical preventive measure despite challenges in production and stability. The ongoing COVID-19 pandemic has further underscored the urgent need for innovative strategies to combat respiratory pathogens and mitigate future pandemics. Despite advancements, there remains a pressing need for more targeted therapies and improved diagnostic tools to address these challenges effectively.
This research topic aims to address the critical challenges posed by drug-resistant pathogens and the urgent need for innovative diagnostic and therapeutic approaches in infectious lung diseases. By fostering interdisciplinary collaboration and integrating emerging technologies such as artificial intelligence and synthetic biology, we seek to advance the development of targeted therapies, improve diagnostic sensitivity and specificity, and personalize treatment strategies. This research topic will highlight ongoing research efforts and facilitate the exchange of ideas to overcome existing challenges and address unmet clinical needs in combating respiratory infections.
To gather further insights in the application of advanced biotechnology and nanotechnology in infectious lung diseases, we welcome articles addressing, but not limited to, the following themes:
- New vaccine developments for viral pneumonia, including influenza A/B, COVID-19, adenovirus, etc.
- Molecular imaging nanoprobes for elucidating the molecular mechanisms of pulmonary infections.
- Smart nanomaterials designed for precise drug delivery or release targeted at pulmonary infections.
- Functional nanomaterials with antiviral, antibacterial, and anti-mycoplasma properties.
This research topic aims to address the critical challenges posed by drug-resistant pathogens and the urgent need for innovative diagnostic and therapeutic approaches in infectious lung diseases. By fostering interdisciplinary collaboration and integrating emerging technologies such as artificial intelligence and synthetic biology, we seek to advance the development of targeted therapies, improve diagnostic sensitivity and specificity, and personalize treatment strategies. This research topic will highlight ongoing research efforts and facilitate the exchange of ideas to overcome existing challenges and address unmet clinical needs in combating respiratory infections.
To gather further insights in the application of advanced biotechnology and nanotechnology in infectious lung diseases, we welcome articles addressing, but not limited to, the following themes:
- New vaccine developments for viral pneumonia, including influenza A/B, COVID-19, adenovirus, etc.
- Molecular imaging nanoprobes for elucidating the molecular mechanisms of pulmonary infections.
- Smart nanomaterials designed for precise drug delivery or release targeted at pulmonary infections.
- Functional nanomaterials with antiviral, antibacterial, and anti-mycoplasma properties.
Keywords: theragnostic, pulmonary infection, nanotechnology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
